What is a transfer of value?

We regularly work with HCPs and HCOs, for example inviting them to speak at medical educational events or seeking their advice and expertise on our services to patients and the healthcare community. Individuals may sometimes be compensated for providing these services to the industry and these payments are referred to as Transfers of Value (ToV).

These can also include, for example, supporting an individual to attend an important medical congress by meeting their registration and reasonable travel and accommodation costs. Organisations may be provided with funding to help with education for healthcare professionals.

How is the code regulated?

In June 2013, the European Federation of Pharmaceutical Industries and Associations (EFPIA) formally adopted the “Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations” to further self-regulate the way pharmaceutical companies collaborate with HCPs or HCOs when a value transfer (e.g., fees for services or educational grants etc) is involved.

In the UK, the requirement to disclose ToV on an individual basis is part of the Association of British Pharmaceutical Industry (ABPI) Code of Practice. The information is published by the ABPI annually at the end of June. Further information about the disclosure of these payments can be found on the ABPI website: www.abpi.org.uk.

Our support for disclosure of transfer of value

Johnson & Johnson Innovative Medicine wholeheartedly supports the code, as we truly believe it enables our interactions to stand up to any scrutiny. We work tirelessly to ensure transparency regarding the financial details of interactions between J&J, HCPs, and HCOs, demonstrating that these interactions are legitimate and with the purpose of improving patient outcomes.

In taking this responsible step, we are ensuring the open cooperation between pharmaceutical companies and HCPs/HCOs continues for the future.

CP-490273 | November 2024